智通财经APP讯，复星医药(600196.SH)公告，公司控股子公司锦州奥鸿药业有限责任公司(“奥鸿药业”)研制的氨甲环酸注射液(“该新药”)用于急性或慢性、局限性或全身性原发性纤维蛋白溶解亢进所致的各种出血的上市注册申请于近日获国家药品监督管理局批准。据悉，该新药本次获批上市，可以为急抢救止血用药提供更多的选择。

","gnid":"9bd9b9956650ba546","img_data":[{"flag":2,"img":[]}],"original":0,"pat":"art_src_3,fts0,sts0","powerby":"hbase","pub_time":1681204860000,"pure":"","rawurl":"http://zm.news.so.com/e59bac85eaac191aed2773b7476cadb0","redirect":0,"rptid":"4ff38f0b4e80defd","rss_ext":[],"s":"t","src":"智通财经","tag":[{"clk":"khealth_1:复星医药","k":"复星医药","u":""},{"clk":"khealth_1:纤维蛋白","k":"纤维蛋白","u":""}],"title":"复星医药(600196.SH)：急抢救止血用药“氨甲环酸注射液”获批上市

扈戚柿4182急救药品,器材及物品应做到的“五定”,是指那五定? -
全诞博15153083218 ______[答案] .定数量品种,定点放置,定人保管,定期消毒灭菌和定期检查维修